LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aktien・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Geschlossen

BrancheGesundheitswesen

58.48 0.43

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

58.12

Max

59.05

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.6B 2.7B
Verkäufe	-1B 11B
KGV Branchendurchschnitt	15.964 49.701
EPS	1.58
Dividendenrendite	4.39
Gewinnspanne	23.309
Angestellte	32,500
EBITDA	1.5B 3.7B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+10.26% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	4.39% 2.39%
Nächstes Ergebnis	30. Juli 2026
Nächste Dividendenausschüttung	31. Juli 2026
Nächstes Ex-Dividendendatum	2. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-940M 117B
Vorheriger Eröffnungskurs	58.05
Vorheriger Schlusskurs	58.48

Nachrichtenstimmung

By Acuity

32%

68%

79 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

N/A / 50.57 Unterstützung & Widerstand

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

10.26% Vorteil

12-Monats-Prognose

Durchschnitt 64.29 USD 10.26%

Hoch 75 USD

Tief 54 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Bristol-Myers Squibb Co. – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 50.57Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

79 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.